1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

TCT 2019: New COAPT Results Support, Durability And Cost-Effectiveness Of Abbott’s MitraClip

 
• By Reed Miller

The three-year results from the COAPT trial confirm Abbott’s MitraClip transcatheter mitral valve replacement device can improve the prognosis of functional heart failure patients. A separate analysis of COAPT showed MitraClip is cost-effective compared to medical therapy.

San Francisco Skyline
• Source: shutterstock.com

New three-year results from the COAPT trial affirm that transcatheter mitral valve repair with Abbott Laboratories’ MitraClip reduces heart failure hospitalizations and mortality compared to medical therapy alone.

The two-year results from COAPT showed mitral repair with MitraClip reduced morality and heart-failure hospitalizations in patients with symptomatic heart failure and moderate-to-severe secondary regurgitation despite taking the medications recommended...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.